Swiss Lions 100 | 2026 edition
Galderma
Galderma is No. 81 in the Swiss Lions 100 and No. 12 in Life Sciences & Health, with a score of 39.0 out of 100. Headquarters: Zug, canton of Zug.
- Swiss Lions score
- 39.0
- Overall rank
- 81of 100
- Life Sciences & Health
- 12of 14
About
Dermatology company headquartered in Zug, behind injectable aesthetics, prescription treatments and skincare brands such as Cetaphil.
How the score is made
Global scale
CHF 4.0bn revenue.
Swiss value
Swiss made: Limited.
Prominence
Online attention across languages, and worldwide search interest.
Impact
No current SBTi target. Not a certified B Corp.
Philanthropy
None found.
Key figures
- Revenue used in the ranking
- CHF 4.0bnTTM Oct 2026, company
- Revenue
- USD 5.9bnTwelve months to 30 June 2026
- Net profit
- USD 863mAttributable to shareholders
- Dividends paid
- USD 104mTo all shareholders
- Employees worldwide
- 7,676
Employees in Switzerland and dividends paid to Swiss shareholders are not published consistently, so they are not shown.
Profile
- Headquarters
- ZugCanton of Zug
- Language region
- German-speaking
- Category
- Life Sciences & Health
- Ownership
- Listed
- Main customers
- Consumers and businesses
- Chief executive
- Flemming ØrnskovSince 2019. Source
- Founded
- 1981
Nearby in the Swiss Lions 100
Also in Life Sciences & Health
1RocheScore 80.8
2NovartisScore 78.6
3LonzaScore 59.5
4SonovaScore 54.8
5SandozScore 54.5
6StraumannScore 53.5
See all 14 brands in Life Sciences & Health.
Sources
- Revenue used in the ranking: stockanalysis.com GALD (TTM Oct 2026).
- Revenue, net profit, dividends and employees: stockanalysis.com, from company filings.
- Climate target: Science Based Targets initiative dashboard, October 2026. Foundations: Swiss commercial register. B Corp: B Lab directory.
Something out of date?
If a figure is wrong, or Galderma can publish figures for the next edition, tell us. Corrections are recorded with their source.